Abstract:OBJECTIVE:To investigate the immune response, in particular, the anti-virus cellular immune response induced by the constructed fusion DNA vaccine CRT (Calreticulin) 180/HPV6E7 in vivo and vitro.METHODS:The HPV6E7 open reading frame was amplified by polymerase chain reaction from pUC/HPV6 plasmid. The CRT180 gene was cloned by reverse transcription from human muscle tissues. The PCR products of CRT180 and HPV6E7 were subcloned into pcDNA3. 1-GFP eukaryotic vector. The recombinant plasmids CRT180/ HPV6E7 was authenticated by restrict enzyme digestion and confirmed by DNA sequencing. The DNA plasmid HPV6E7 with report gene GFP was transfected to murine B16 cells by lipofectamine kit to establish the target cells. The HPV6E7-expressing cell line was selected by G418 and identified by RT-PCR. The C57BL/6 mice were vaccinated via intramuscular injection in the right legs with 100 microg plasmid encoding CRT180-HPV6E7, CRT180 or HPV6E7, empty plasmid without insert, and PBS group respectively. The changes of the T lymphocyte subsets in the peripheral blood of the mice were evaluated by flow cytometric analysis. The lymphocytes from the spleen and lymph nodes were harvested and co-cultured with HPV6E7-expressing cell lines. The CTLs kill activity and the cytokines IL-2, IFN-gamma secretion levels of the lymphocytes were assessed by LDH and ELISA respectively.RESULTS:The constructed recombinant plasmids pcDNA3. 1-CRT180/HPV6E7, pcDNA3. 1-CRT180 and pcDNA3. 1-HPV6E7 were authenticated by restrict enzyme digestion and confirmed by DNA sequencing. Green fluorescence located in the cellular nucleus and plasma could be detected by fluorescent microscope after transfection with plasmids. The results of RT-PCR from the selected positive cell line showed the expected fragments of HPV6E7 mRNA. After immunization, the percentage of CD8+ or TCRgamma delta tau cells in the peripheral blood, the CTLs kill activity of the spleen cells and lymphocytes against HPV6E7-expressing cells, and the secretion levels of IL-2, IFN-gamma in CRT180/HPV6E7 vaccinated group increased significantly compared with the control groups (P < 0.05).CONCLUSION:Vaccination with fusion DNA vaccine CRT180/HPV6E7 could elicit a more efficient HPV6E7-specific immune response than with HPV6E7 plasmid, indicating the potential of CRT180/HPV6E7 vaccine to enhance the antigen presentation. The recombinant CRT180/HPV6E7 might help the elimination of virus in animal models and accordingly be used as a vaccine candidate in the therapy of CA.

[Construction and Immunological Evaluation of Recombinant Adenovirus Containing Codon-Modified HPV 16 L1 Gene].

[Immune Response Induced by Vaccination with Pseudotyped Raav1 Expressing HPV16 L1 Protein].

One-prime Multi-Boost Strategy Immunization with Recombinant DNA, Adenovirus, and MVA Vector Vaccines Expressing HPV16 L1 Induces Potent, Sustained, and Specific Immune Response in Mice.

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

The Construction and Immune Response of Fusion DNA Vaccine CRT180/HPV6E7

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

Expression of human papillomavirus type16 late gene (L1) in prokaryotic cells and its immune effict observation

Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice

Construction and Expression of a Recombinant Adenovirus Encoding E6-E7 Fusion Proteins of Hmnan Papillomavirus Subtypes 16, 18, and 58

Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease.

[Immunogenicity of Plasmid DNA and Adenoviral Vectors Encoding HIV-1 Subtype B Env Gene].

Construction of a Chimeric Gene of Human Papillomavirus Type 16 L1-E7 and Immunogenicity of Expressed Fusion Protein

Induction of Cross-Neutralizing Antibodies by Sequential Immunization with Heterologous Papillomavirus L1VLPs and Its Implications for HPV Prophylactic Vaccines.

Immune Protection and Mechanism of Plasmid DNA Encoding Gglycoprotein of Respiratory Syncytial Virus(rsv)

The Construction of Recombinant Adenovirus Inserted with Modified Epstein-Barr Virus Latent Membrane Protein 1 and the Study of Its Immune Effect

[Construction and Immunological Responses of Recombinant Adenovirus Containing Epstein-Barr Nuclear Antigen 1 in Mice].

Recovery of select rare and fastidious microorganisms from blood cultures.

[Study on the Immunogenicity of Adeno-Vector Vaccine Against H5N1 Influenza A Virus].

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

The Specific Immune Response Elicited by Recombinant CRT120/HPV6bE7 DNA Vaccine in Mice